Left Ventricular Morphology and Function in Patients with Atherosclerotic Renovascular Disease

Wright, Julian; Shurrab, Ala’a E.; Cooper, Andrew A.; Kalra, Paul R.; Foley, Robert N.; Kalra, Philip A.

doi:10.1681/asn.2005010043

Cited by 97 publications

(58 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ARVD patients have a high cardiovascular mortality; they sometimes present with heart failure, and recent reports indicate a ASTRAL trial of revascularization in ARVD patients S Mistry et al much higher prevalence of cardiac structural and functional abnormalities in these patients than in those with chronic kidney disease of other aetiology. 7 Systematic study of the effects of renal intervention upon the heart has never previously been undertaken, so assessment of whether or not renal revascularization in patients with ARVD leads to significant improvements in cardiac structure and function is an important question. One sub-study is assessing these parameters with echocardiography (sample size 150 patients) and the other with cardiac MR imaging (sample size 68 patients), the latter being funded by the British Heart Foundation.…”

Section: Cardiac Substudiesmentioning

confidence: 99%

Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far

et al. 2007

View full text Add to dashboard Cite

Section: Cardiac Substudiesmentioning

confidence: 99%

Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far

et al. 2007

View full text Add to dashboard Cite

“…11 Studies have shown that the Optimising care at the cardio-renal interface Donah Zachariah degree of blood pressure reduction, ultrafiltration volume, age and troponin T levels are associated with the development of significant regional wall motion abnormalities (cardiac stunning) in haemodialysis. 12 It is believed that this in turn leads to myocardial hibernation, increased levels of N-terminal prohormone brain natriuretic peptide (NT-pro BNP), ventricular arrhythmias and reduction in overall systolic function.…”

Section: Impact Of Haemodialysis On Cardiovascular Statusmentioning

confidence: 99%

Optimising care at the cardio-renal interface

Zachariah

2010

Clinical Medicine

View full text Add to dashboard Cite

“…Previous studies have shown that about 40% of patients with renovascular stenosis are complicated with cardiac diastolic dysfunction, such as heart failure with preserved ejection fraction (HFpEF) (Little and Brucks, 2005;Wright et al, 2005;Asrar ul Haq et al, 2014). The progression of HFpEF reportedly is accelerated by myocardial ischemia (Middleton et al, 2001;Ronco and di Lullo, 2014).…”

Section: Introductionmentioning

confidence: 99%

Concomitant coronary and renal revascularization improves left ventricular hypertrophy more than coronary stenting alone in patients with ischemic heart and renal disease

Dong

Huang

Luo

et al. 2016

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Percutaneous transluminal renal artery stenting (PTRAS) has been proved to have no more benefit than medication alone in treating atherosclerotic renal artery stenosis (ARAS). Whether PTRAS could improve left ventricular hypertrophy (LVH) and reduce adverse events when based on percutaneous coronary intervention (PCI) for patients with coronary artery disease (CAD) and ARAS is still unclear. A retrospective study was conducted, which explored the effect of concomitant PCI and PTRAS versus PCI alone for patients with CAD and ARAS complicated by heart failure with preserved ejection fraction (HFpEF). A total of 228 patients meeting inclusion criteria were divided into two groups: (1) the HFpEF-I group, with PCI and PTRAS; (2) the HFpEF-II group, with PCI alone. Both groups had a two-year follow-up. The left ventricular mass index (LVMI) and other clinical characteristics were compared between groups. During the follow-up period, a substantial decrease in systolic blood pressure (SBP) was observed in the HFpEF-I group, but not in the HFpEF-II group. There was marked decrease in LVMI in both groups, but the HFpEF-I group showed a greater decrease than the HFpEF-II group. Regression analysis demonstrated that PTRAS was significantly associated with LVMI reduction and fewer adverse events after adjusting for other factors. In HFpEF patients with both CAD and ARAS, concomitant PCI and PTRAS can improve LVH and decrease the incidence of adverse events more than PCI alone. This study highlights the beneficial effect of ARAS revascularization, as a new and more aggressive revascularization strategy for such high-risk patients.

show abstract

Left Ventricular Morphology and Function in Patients with Atherosclerotic Renovascular Disease

Cited by 97 publications

References 29 publications

Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far

Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far

Optimising care at the cardio-renal interface

Concomitant coronary and renal revascularization improves left ventricular hypertrophy more than coronary stenting alone in patients with ischemic heart and renal disease

Contact Info

Product

Resources

About